According to the information from Zhitong Finance APP, on August 14th, in the Hong Kong stock market, Beishui (Northbound funds) had a net selling of HKD 1.041 billion. Among them, the net selling through the Shanghai-Hong Kong Stock Connect was HKD 895 million, and the net selling through the Shenzhen-Hong Kong Stock Connect was HKD 146 million.
The top three stocks with the highest net buying by Beishui were China Mobile (00941), WuXi Biologics (02269), and Xiaomi Corporation-W (01810). The top three stocks with the highest net selling by Beishui were Yingfu Fund (02800), CSOP HS TECH (03033), and China Construction Bank (00939).
Active trading stocks through the Shanghai-Hong Kong Stock Connect
Active trading stocks through the Shenzhen-Hong Kong Stock Connect
China Mobile (00941) received a net buying of HKD 529 million. On the news front, CITIC Securities pointed out that China Mobile's overall operations remain stable. In the personal market, with the background of slowing growth in data traffic, the company strengthens the integration of applications, equity, and terminals, striving to maintain stability in the personal market; in the home market, while promoting the continuous penetration of gigabit broadband, it enhances &#34;smart home + content&#34; drive to increase comprehensive home broadband ARPU; in the government-enterprise market, it continues to deepen industry cultivation, enhance core capabilities, and improve the profitability of B-end projects. Calculated at a 72% dividend payout ratio, the current dividend yield of the company is approximately 7% for H shares and approximately 4.5% for A shares, making the dividend return still attractive.
WuXi Biologics (02269) received a net buying of HKD 60.74 million. On the news front, Guosheng Securities pointed out that CXO is expected to benefit from the expected innovation sentiment and water level rise brought by the encouragement of innovation policy throughout the entire chain, especially with the expected domestic industry policy support, the potential improvement in investment and financing may lead to a recovery in the domestic front-end business. After a long period of adjustment, the sector's valuation and positions are at historical lows, and negative expectations such as changes in the innovative drug environment are basically reflected in the current valuation, with little short-term risk.
SMIC (00981) received a net buying of HKD 47.29 million. On the news front, Pu Yin International Research pointed out that SMIC is in a trend of semiconductor fundamentals improvement. The company guided that the median revenue for the third quarter increased by 14% month-on-month, with a central gross margin of 19%, a significant increase of 5.1 percentage points month-on-month
This is mainly due to the drive of local demand, leading to a supply shortage of 12-inch capacity, optimization of product structure, and improving prices. The company expects the 12-inch capacity to increase by about 60,000 pieces by the end of this year, exceeding the previous plan.
China Medical (01177) suffered a net sell-off of HKD 57.15 million. On the news front, Jefferies released a report stating that China Medical's mid-term revenue increased by 11% year-on-year, and net profit doubled. Excluding the sale of Shandong Xinhua and other one-time transactions, adjusted net profit increased by 14% year-on-year. The group obtained approval for four innovative drugs in the first half of the year. New products and innovative drugs launched within five years contributed approximately 38% and 39% of the revenue, higher than the 30% and 37% in the first half of last year.
Tencent (00700) faced a net sell-off of HKD 141 million before its performance announcement. In terms of news, Tencent Holdings released its performance after the market closed. The revenue in the second quarter was RMB 161.12 billion, slightly below the estimated RMB 161.35 billion, an 8% year-on-year increase; the adjusted net profit in the second quarter was RMB 57.31 billion, a 53% year-on-year increase. In addition, Tencent Holdings announced that it repurchased a total of 154 million shares for approximately HKD 52.3 billion in the first half of the year.
Hong Kong ETFs were sold off. GF Fund (02800), CSOP HS TECH (03033), and HSCEI (02828) suffered net sell-offs of HKD 1.469 billion, HKD 539 million, and HKD 154 million respectively. On the news front, Guoyuan International stated that based on its assessment of the market environment, the bank holds a relatively cautious and optimistic attitude towards the future trend of Hong Kong stocks, and expects more domestic policy dividends to boost market investor confidence in the medium to long term. CICC stated that Hong Kong stocks have some &#34;favorable conditions.&#34; If policies can continue to exert force during this opportunity, it will provide more support for subsequent capital inflows and market rebounds.
In addition, Xiaomi Group-W (01810) saw a net buy-in of HKD 59.3 million. Meanwhile, CNOOC (00883) and China Construction Bank (00939) suffered net sell-offs of HKD 97.88 million and HKD 185 million respectively

WXXWY

STECH

02269

513130

80941

600941

03033

00941

On August 14, the net selling of Beishui in the Hong Kong stock market was HKD 1.041 billion. Among them, the net selling of the Shanghai-Hong Kong Stock Connect was HKD 0.895 billion, and the net selling of the Shenzhen-Hong Kong Stock Connect was HKD 0.146 billion. The stocks with the most net buying were China Mobile, WuXi Biologics, and Xiaomi Group, while the most net selling were Yingfu Fund, CSOP HS TECH, and China Construction Bank. Industry analysis points out that China Mobile operates steadily, WuXi Biologics and SMIC International Semiconductor are favored by policy support and the uptrend in semiconductor demand

- In the Hong Kong stock market on August 14, Northbound trading saw a net sell-off of 10.41 billion HKD, with the Shanghai-Hong Kong Stock Connect net selling 8.95 billion HKD and the Shenzhen-Hong Kong Stock Connect net selling 1.46 billion HKD. 
- Top buys by Northbound investors were China Mobile (00941), WuXi Biologics (02269), and Xiaomi Corporation-W (01810), while top sells included E Fund Management (02800), Southbound HS Tech (03033), and China Construction Bank (00939).
- China Mobile's stable operations and dividend yield remain attractive, while WuXi Biologics is expected to benefit from innovation policies. SMIC is on an upward trend in the semiconductor sector, and Tencent's Q2 revenue slightly missed estimates but showed a significant profit increase.

Zhitong

WuXi Biologics

Hang Seng TECH Index

WUXI BIO

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

CHINA MOBILE-R

China Mobile

CSOP HS TECH

CHINA MOBILE

Beishui Movement | Beishui net sold 1.041 billion Tencent shares after hours, Tencent's pre-performance was sold off by over 100 million Hong Kong dollars